Studies have confirmed that DPP-4 inhibitors exhibit renoprotective effects via inhibiting inflammation and oxidative stress, preventing podocyte injury, and delaying glomerulosclerosis in DKD (Kawanami et al., 2021; Kubo et al., 2020; Mima, 2022). The gene discussed is DPP4; the disease is diabetic kidney disease.